Acute Kidney Injury in Pediatric Treated with Vancomycin and Piperacillin-Tazobactam in Tertiary Care Hospital

Table 4

Outcomes (AKI and LOS) and use of concomitant nephrotoxins, vancomycin trough, daily vancomycin dose, and duration of therapy in overall and by treatment. N = 248.

Groups
Factor	All; Patients; (n=248)	Vancomycin; (n=36)	Vancomycin; +; PTZ; (n=62)	Vancomycin; +; Ceftazidime; (n=99)	Vancomycin; +; Ceftriaxone; (n=51)
AKI cases	4 (1.6)	0 (0.0)	3 (4.8)	0 (0.0)	1 (2.0)
Use of concomitant nephrotoxic medication	76 (30.6)	10 (27.8)	21 (33.9)	33 (33.3)	12 (23.5)
Duration of therapy (days)
Mean ± SD	7.2 ± 7.2	9.1 ± 13.9	7.1 ± 4.9	7.4 ± 5.9	5.8 ± 4.5
Median (IQR)	5.0 (4.0-8.0)	5.0 (4.0-6.0)	5.0 (4.0-9.0)	6.0 (4.0-8.0)	5.0 (4.0-7.0)
Initial vancomycin trough level (mg/L)
Mean ± SD	9 ± 5.2	9 ± 4.9	9 ± 5.5	8.7 ± 5.2	9.3 ± 5.2
Daily vancomycin dose (mg/kg/day)
Mean ± SD	45.8 ± 14.1	44.2 ± 14.3	49.2 ± 13.7	43 ± 13.4	48.5 ± 14.7
Total LOS (days)
Mean ± SD	24.7 ± 37.5	13.0 ± 13.5	41.8 ± 49.2	25.6 ± 39.8	10.3 ± 9.2
Median (IQR)	11.0 (7.0-21.8)	8.5 (6.0-14.0)	19.5 (10.0-60.0)	12.0 (8.0-21.0)	7.0 (6.0-12.0)

Difference is highly significant (p<0.001).